Karyopharm Therapeutics Inc

NASDAQ:KPTI  
8.28
+0.55 (+7.12%)
Earnings Announcements

Karyopharm Announces Preliminary Unaudited Fourth Quarter And Full Year 2021 Net Product Revenues And Outlines 2022 Objectives

Published: 01/10/2022 12:13 GMT
Karyopharm Therapeutics Inc (KPTI) - Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Net Product Revenues and Outlines 2022 Objectives.
Karyopharm Therapeutics - Sees Net Product Revenues of Xpovio to Be About $29.7 Million for Q4 Based on Preliminary Unaudited Financial Information.
Revenue is expected to be $40.57 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $32.34 Million
Next Quarter EPS Guidance is expected to be -$0.63

More details on our Analysts Page.